Rakovina Therapeutics: Advancing AI Driven Cancer Therapies

Market Focus

Rakovina Therapeutics is a clinical stage biopharmaceutical company applying artificial intelligence to accelerate the discovery and development of therapies targeting the DNA damage response pathway, a critical mechanism in the treatment of cancer. With global oncology markets expected to exceed $250 billion by the end of the decade, the company is addressing urgent demand for next generation therapies that overcome resistance, improve patient outcomes, and expand treatment options across multiple tumor types. Rakovina’s focus on DDR targets positions it at the forefront of precision oncology innovation.

Platform and Technology Strategy

At the core of Rakovina’s approach are its Deep Docking and Enki AI platforms, proprietary systems that combine computational chemistry and machine learning to design and optimize small molecule drug candidates with enhanced potency, metabolic stability, and central nervous system penetration. These platforms allow the company to rapidly evaluate billions of potential compounds, identifying best in class candidates for clinical development. The pipeline includes the kt2000AI PARP inhibitors and the kt3000 and kt5000 series, which extend beyond PARP to additional DDR pathways, representing a differentiated strategy compared with traditional oncology drug discovery.

Recent Progress – Growth and Partnerships

Rakovina entered the second half of 2025 with strong momentum. The company raised more than CAD 4.9 million through a private placement and convertible debenture financing, strengthened its board with new expertise in finance and science, and achieved DTC eligibility to expand access for US investors. Trading on both the TSX Venture Exchange and the Frankfurt exchange, Rakovina is building an international shareholder base. Recent preclinical data presented at leading scientific conferences demonstrated promising drug like properties of its lead candidates, including long half life, improved clearance, and early indications of brain penetration.

Partnerships, Funding and Strategic Positioning

The company is executing a strategy that combines financing, scientific collaboration, and investor outreach to advance its programs efficiently. With a cash balance of approximately CAD 1.9 million as of June 30, 2025, plus new funding raised in Q2, Rakovina has the resources to progress its pipeline into the next phase of development. Partnerships with academic and research institutions enhance validation of its AI enabled discoveries, while its listing on multiple exchanges improves visibility and access to global capital. The focus on DDR targets provides a clear niche in oncology where demand for new therapies is growing.

Leadership and Capital Markets Strategy

Rakovina is led by Executive Chairman Jeffrey Bacha, who has decades of experience in oncology drug development and public company leadership. He is supported by a management team and scientific advisors with deep expertise in DNA damage response biology, computational drug design, and clinical strategy. The company is publicly listed on the TSX Venture Exchange under ticker RKV and also trades in Europe, providing investors with exposure to a high growth biopharma platform leveraging AI in oncology drug discovery.

Near Term Catalysts

• Advancement of kt3283 from the kt3000 series into development collaboration studies

• Additional preclinical data from the kt2000AI and kt5000AI series expected in Q4 2025

• Expansion of investor and partner outreach in North America and Europe

• Potential new collaborations to accelerate clinical development and non dilutive funding opportunities

• Continued adoption of AI technologies in oncology research driving sector wide interest

  
  

Conclusion

Rakovina Therapeutics offers investors a unique opportunity to participate in the convergence of artificial intelligence and oncology drug discovery. With its proprietary platforms, differentiated pipeline, strengthened balance sheet, and growing global presence, the company is strategically positioned to create significant value as it advances novel DDR inhibitors toward clinical development.

Interested in Attending or Presenting?

🔹 Prospective Attendees: Click here to join our upcoming investor events and discover emerging opportunities across the resource, biotech, and technology sectors.

🔹 Companies Seeking Exposure: Click here to learn how to present at one of our curated investor showcases and connect with active family offices, funds, and high-net-worth investors.

For additional info or to schedule a call, feel free to reach out.

Jimmy Lederer

Vice President

Trinity Financing Investments Corporation

Phone: 347-514-0000

Email: jimmy@trinityfinancinginvestments.com

All content provided is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect to any products or services. The content presented should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. There are inherent risks involved with investing in Issuers, as set out in the public disclosure record of each Issuer. Issuers are not responsible for revising or updating any information that they present via TFIC events.

Investors should refer to the continuous disclosure documents filed by each Issuer under applicable securities laws, including risk factors and warnings regarding “forward looking information”. Issuers are solely responsible for compliance with applicable securities laws, and TFIC makes no representations and provides no assurances to Investors regarding the accuracy or truthfulness of information presented by Issuers via TFIC events or in their public disclosure records. 

TFIC does not recommend or endorse any Issuer that presents via TFIC events, nor does TFIC verify the accuracy of any information presented by Issuers to Investors via TFIC events or in their public disclosure records. TFIC’s sole responsibility as the operator of TFIC events is to provide a platform for Investors and Issuers to communicate directly.

ALL CONTENT PRESENTED BY ISSUER(S) IS PROVIDED BY THE ISSUER(S) "AS IS" AND “AS AVAILABLE”. TFIC DOES NOT GUARANTEE THE ACCURACY OF ITS CONTENT. BY ATTENDING, EACH INVESTOR AGREES TO ACCEPT ANY RISKS ASSOCIATED AND ACKNOWLEDGES THAT TFIC IS NOT RESPONSIBLE FOR ANY CONTENT PRESENTED BY OR RELATING TO ISSUERS ON THE PLATFORM. 

TFIC DOES NOT WARRANT THAT THE PROVISION OF INFORMATION BY ISSUERS IN THEIR PRESENTATION WILL BE ERROR-FREE, TIMELY, COMPLETE OR ACCURATE. ATTENDANCE AND RELIANCE ON INFORMATION RECIEVED THEREON IS AT INVESTOR’S SOLE RISK. TFIC WILL NOT BE IN ANY WAY BE LIABLE TO ANY INVESTOR OR ISSUER OR ANY OTHER ENTITY OR PERSON FOR ANY INACCURACIES, ERRORS, OMISSIONS, DELAYS, DAMAGES, CLAIMS, LIABILITIES OR LOSSES, REGARDLESS OF CAUSE, IN OR ARISING FROM THE USE OF THE PLATFORM.

IN NO EVENT WILL TFIC BE LIABLE FOR ANY DAMAGES, INCLUDING WITHOUT LIMITATION DIRECT OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES ARISING IN CONNECTION WITH THE ATTENDANCE BY INVESTORS AND/OR ISSUERS EVEN IF TFIC IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, LOSSES OR EXPENSES. FURTHER, TFIC SHALL NOT BE LIABLE IN ANY MANNER FOR THE PRODUCT OR SERVICES OF ANYONE WHO REDISTRIBUTES THE INFORMATION PROVIDED ON THE PLATFORM, AND SUCH REDISTRIBUTION IS EXPRESSLY PROHIBITED.